10:19 AM EST - Numinus Wellness Inc. : Announced that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) , a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) , the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs. "We are excited to share an update on the progress of our MDMA compassionate access trial with the full recognition that existing therapies for PTSD are inadequate," said Payton Nyquvest , CEO of Numinus. "At Numinus, we are pleased to help foster a promising regulatory landscape that will contribute to a better understanding that psychedelic-assisted psychotherapies are a viable, safe, and necessary avenue for expanding existing treatment options. We look forward to continued collaboration with the Multidisciplinary Association of Psychedelics for Studies (MAPS PBC) and will work together to provide those experiencing PTSD with more treatment options." Numinus Wellness Inc.
shares V.NUMI are trading down 7 cents at $1.73.
